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Abstract
Background: The Australian Institute of Health and Welfare’s first report into acute kidney injury demonstrated a
significant increase in the incidence of acute-tubulo interstitial nephritis, the ICD-10 code representing both acute
interstitial nephritis and pyelonephritis, in women aged less than 55 years. In contrast, recent case series have reported
rising rates of drug induced acute interstitial nephritis predominantly among elderly patients. Due to several limitations
with the Australian Institute of Health and Welfare report, this new trend requires further investigation to determine if
rates of acute interstitial nephritis are truly increasing among younger Australian women.
Methods: Patients who underwent a renal biopsy at a single center from 2000 to 2015 were reviewed and those with
biopsy confirmed acute interstitial nephritis were selected. Cause of acute interstitial nephritis, patient demographics,
co-morbidities and renal indices for these patients when available were recorded and compared.
Results: Eight hundred ninety-eight patients who underwent renal biopsy from 2000 to 2015 were reviewed and 40
patients were identified with biopsy confirmed acute interstitial nephritis. The rate of acute interstitial nephritis
increased significantly over the study period (4 patients/2.2% of biopsies performed in 2000–03 vs. 19 patients/6.7% of
all biopsies performed in 2012–15; p = 0.002). There was a marked increase in the number of women with AIN in the
last four years of the study (2 patients and 2.1% of biopsies performed in women in 2000–2003 compared with 13
patients and 9.0% of biopsies performed in women in 2012–2015). Immune mediated causes of acute interstitial
nephritis and NSAID associated AIN were more common in women (9 females vs. 3 males), occurred more frequently
in the last eight years of the study and predominantly in patients under 55 years of age.
Conclusions: Our study demonstrates a significant increase in the number of patients with biopsy confirmed AIN. Also,
we provide preliminary evidence in support of an increase in rates of younger women with immune mediated acute
interstitial nephritis. These results support the findings of the Australian Institute of Health and Welfare and suggest
that younger women may be at higher risk of immune mediated and NSAID associated acute interstitial nephritis.
Keywords: Acute interstitial nephritis, Acute kidney injury, AIHW
Background
Acute interstitial nephritis (AIN) is an immune mediated
condition that is characterized by an inflammatory infil-
trate in the kidney interstitium and is a well-recognized
cause of acute kidney injury (AKI). The incidence of
AIN is increasing worldwide and previous studies have
ascribed this to a surge in drug induced AIN in elderly
patients [1–5]. The Australian Institute of Health and
Welfare (AIHW) recently released their first national
report into acute kidney injury [6]. That snapshot
reviewed hospital ICD-10 coding to assess the causes
and incidence of AKI over the last 15 years in Australia.
Surprisingly, this showed that since 2008 there has been
a significant increase in the incidence of acute tubulo-
interstitial nephritis (the ICD-10 code for both AIN and
acute pyelonephritis) in women less than 55 years of age
with acute tubulo-interstitial nephritis now representing
* Correspondence: gregory.wilson@health.qld.gov.au
1Department of Renal Medicine, Royal Brisbane and Women’s Hospital,
Herston, QLD 4029, Australia
2CKD.QLD & NHMRC CKD.CRE, The University of Queensland, Herston, QLD,
Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wilson et al. BMC Nephrology  (2017) 18:329 
DOI 10.1186/s12882-017-0747-7
the most common cause of hospitalization from AKI in
women in this age group [6]. An increased risk of AIN
in younger women has not been previously reported and
the Australian experience is an emerging phenomenon
at odds with previous findings of increasing rates of AIN
in elderly patients.
Before these conclusions can be made, however, sev-
eral limitations in the AIHW report must be addressed
by further research. Specifically, ICD-10 coding is impre-
cise, with AIN and pyelonephritis included as one ICD-
10 code. As such the AIHW report is unable to deter-
mine which of these two entities is increasing. A case
series of patients with biopsy-confirmed AIN would pro-
vide preliminary evidence to investigate if the new trends
reported by the AIHW are being driven by increasing
rates of AIN in younger women. Furthermore, while the
AIHW report recorded patient age and gender it was
not able to record other key patient factors, such as the
causes of acute tubulo-interstitial nephritis, which might
underlie their reported trend.
The present study seeks to address the limitations of the
AIWH report by examining a cohort of patients with bi-
opsy confirmed AIN in a single center to explore (a)
whether there has been an increase in the rates of AIN
and when this change began, (b) whether there was a dis-
proportionate rise in AIN in younger women and (c) the
causes, characteristics and outcomes of patients with AIN.
Methods
Design and implementation of this single-center retro-
spective observational cohort study was subject to insti-
tutional human research ethics committee review
(HREC/15/QRBW/544) as a quality assurance and clin-
ical audit activity. The study was undertaken at the
Royal Brisbane and Women’s Hospital, a tertiary referral
hospital that undertakes all public renal biopsies for
northern Brisbane and surrounding regional hospitals in
Queensland, with a catchment area of approximately
one and a half million people.
Figure 1 describes the patient selection process. Adults
(18 years and over) with AIN were identified through a
database search of all patients from the Royal Brisbane
and Women’s Hospital who underwent renal biopsy
from the 1st of January 2000 until the 31st of December
2015 using the keywords ‘Interstitial’ and ‘Nephritis’
within kidney biopsy reports. Biopsy results were manu-
ally reviewed to identify patients with a histological diag-
nosis of AIN. AIN was defined as the presence of an
inflammatory infiltrate within the interstitium with or
without tubulitis. The diagnosis was determined by two
expert kidney histopathologists who were continuously
employed over the study period. The degree of interstitial
infiltration, type of cellular infiltrate, the presence of tubu-
litis and immunofluorescence were recorded. Patients
who had a second coexistent histological diagnosis at the
time of biopsy of either acute tubular necrosis or acute
glomerulonephritis were excluded. Patients with positive
urine cultures were also excluded. This was to ensure that
only patients with a single diagnosis of AIN and no other
acute pathology were included.
Medical records of the patients were reviewed. Patient
demographics (age, gender, date of death, co-morbidities),
AIN characteristics (presumed cause as determined by the
treating nephrologist, treatment, renal replacement ther-
apy, co-existent disease on biopsy) and renal indices
(serum creatinine at biopsy, urine white cells, urinary eo-
sinophils, urine protein creatinine ratio, Acute Kidney In-
jury Network stage) were recorded. When available,
serum creatinine levels two weeks post biopsy and final
serum creatinine measured were recorded if they were at
least three months after the initial biopsy. When available,
serum creatinine levels three to twelve months prior to bi-
opsy were also recorded for a baseline serum creatinine.
The AIN etiology was categorized into 6 groups based
on a classification system used in previous case series
[1]: antibiotic, non-steroidal anti-inflammatory drugs
(NSAIDs), proton pump inhibitors (PPIs)/ H2 antago-
nists, immune mediated diseases (including tubulointer-
stitial nephritis and uveitis), other causes and unknown
cause. Patients were assigned to the unknown cause
group when the cause of AIN had not able to be deter-
mined by the treating team. Treatment administered
was categorized into steroid therapy or no steroid ther-
apy. No distinction was made between different formula-
tions of steroids or routes of administration. Urine white
cells were classified into three categories of less than 10
Fig. 1 Flow diagram of patient selection process
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WCC per high-powered field (HPF), 10–100 WCC/HPF
and more than 100 WCC/HPF. The Acute Kidney Injury
Network (AKIN) stage was calculated using the serum
creatinine at the time of biopsy divided by the serum
creatinine measured in the 3–12 months prior to biopsy.
Data processing and statistical analyses were per-
formed using R (3.2.4, R Foundation for Statistical Com-
puting, Vienna, Austria) [7]. Dichotomous variables were
displayed as counts with percentages; categorical vari-
ables were displayed as counts with relative frequencies
(%). Continuous variables were assumed to be non-
parametric and therefore were displayed as medians with
interquartile ranges. Pearson Chi Square test of best fit
was used to determine differences in categorical vari-
ables. Differences in serum creatinine at different time
points between patient subgroups were assessed using
Mann-Whitney U test for dichotomous variables and
Kruskal-Wallis test for categorical variables.
Results
Patient demographics and co-morbidities are outlined in
Table 1. Biopsy confirmed acute interstitial nephritis was
identified in only 40 patients (4.4% of all biopsy per-
formed), of whom 55% were female. Although this rela-
tively small sample size limits both the statistical power
of this study and the conclusions that can be drawn
from the analyses, the data will nevertheless be explored
in order to characterize emerging trends in biopsy con-
firmed AIN within a single Australian center over a
16 year period.
Patient co-morbidities were similar across both gen-
ders. Patients with immune-mediated diseases including
tubulo-interstitial nephritis with uveitis (TINU) as the
cause of their AIN were younger than those with other
causes of AIN (median age 40.7 years vs. 63.9 years in
patients with other causes of AIN) however, this did not
reach significance. Patients with proton pump inhibitor
or H2 antagonist (PPI/H2) use and antibiotic use as the
cause of their AIN were older than those with other
causes (median age 72.3 years and 66.8 years respect-
ively). Neither gender nor co-morbidities were signifi-
cantly different by age.
The numbers of patients with AIN were compared
over 4 year intervals. There was an increase in the num-
ber of patients with biopsy proven AIN over the study
period with only four patients identified in 2000 to 2003
compared with nineteen patients from 2012 to 2015
(p = 0.002). There was also an increase in the percentage
of patients with AIN as a proportion of all patients who
underwent renal biopsy, with 2.2% of all patients with a
renal biopsy diagnosed with AIN in 2000 to 2003 com-
pared to 6.7% of patients with a renal biopsy in 2012–
2015. There was an increase in the number of both male
and female patients with AIN during the study. Fig. 2
describes the increase in AIN in men and women as a
percentage of the total number of men and total number
of women who underwent renal biopsies over the study
period. In the last four years of the study there was
marked increase in the percentage of women with AIN
on renal biopsy (2 patients and 2.1% of all biopsies per-
formed in women in 2000–2003 compared with 13 pa-
tients and 9.0% of all biopsies performed in women in
2012–2015) and a less marked increase in men with
AIN (2 patients and 2.3% of all biopsies performed in
men in 2000–2003 compared with 6 patients and 4.3%
of all biopsies performed in men in 2012–2015).
AIN characteristics and patient outcomes
Table 2 describes the renal indices at time of biopsy. As
expected, serum creatinine values were raised in the ma-
jority of patients (95%) at the time of diagnosis. Serum
creatinine values were higher in males compared to fe-
males though this was not significant. Patients with anti-
biotics as the cause of their AIN had higher elevations in
serum creatinine while those with NSAID and immune
mediated causes of AIN had lower serum creatinines.
Table 1 Patient Characteristics and Comorbidities
Male Female Total
N 18 (45%) 22 (55%) 40
Age at biopsy (IQR) 59.7 yrs. (42.5–78.0) 58.2 yrs. (37.8–67.0) 58.6 yrs. (40.3–74.5)
Comorbidities (%) (%) (%)
Ischaemic Heart Disease 5 (28) 1 (5) 6 (15)
Hypertension 8 (44) 8 (36) 16 (40)
Dyslipidaemia 4 (22) 5 (23) 9 (22.5)
Diabetes Mellitus (type 1 or 2) 7 (39) 5 (23) 12 (30)
Autoimmune disease 4 (22) 6 (27) 10 (25)
PPI use 6 (33) 7 (32) 13 (32.5)
Cancer (active or in remission) 7 (39) 4 (18) 11 (27.5)
Mental Health diagnosis 2 (11) 6 (27) 8 (20)
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The majority of patients had sterile pyuria and protein-
uria with varying degrees of severity. Urinary eosinophils
were only tested in a minority of patients.
All patients had evidence of an interstitial infiltrate on
renal biopsy histology. Lymphocytes were present in the
interstitial infiltrate in all patients while eosinophils were
seen in 32 patients, plasma cells in 17 patients and neu-
trophils were noted in only 3 patients. Tubulitis was
present in 38 of the 40 patients. Immunofluorescence
was negative in the majority of patients (30/40). Five
patients had 1–2+ IgG staining which was linear in the
glomerular and tubular basement membrane in four pa-
tients and diffusely distributed in the remaining patient.
Those patients with linear IgG staining had other histo-
logical findings consistent with diabetic nephropathy
and the patient with diffuse IgG staining did not have a
cause of AIN identified. 4 patients had trace-1+ IgM
staining within the mesangium and 3 of these patients
had a drug induced cause of AIN (antibiotics or hydro-
chlorothiazide use) while the cause of AIN in the other
patient was not identified. One patient had 2+ IgA stain-
ing in the mesangium and the cause of AIN in this pa-
tient was NSAID use.
Table 3 describes the presumed causes of AIN. Most
commonly, no cause was identified as the precipitant for
AIN (unknown cause). Antibiotic use was the second most
frequently reported cause of AIN (7, 17.5%), with penicillin
as the most common antibiotic class to precipitate AIN (4,
10%). Tubulo-interstitial nephritis with uveitis (4, 10%) was
the most common immune mediated cause followed by
sarcoidosis (2, 5%) and Sjogren’s Syndrome (1, 2.5%). Other
causes included a patient with oxalate nephropathy, a pa-
tient with hydrochlorothiazide use and a patient with lamo-
trogine use as the precipitant. Compared with men, women
were more likely to have NSAID associated AIN (4 females
vs. 1 male) and immune mediated AIN (5 female vs. 2
male). Immune mediated AIN and NSAID associated AIN
occurred only in patients from 2008 onwards.
Fig. 2 Percentage of Renal Biopsies with AIN by Year of Diagnosis
Table 2 Renal Indices at time of Biopsy
Renal Indice
Urine White Cells (per HPF) (%)






Not tested 33 (82.5)
Urine Protein Creatinine Ratio (%)
Less than15 mg/mmol Cr 5 (12.5)
More than15 mg/mmol Cr 22 (55)
Not tested 13 (32.5)
Co-existent Disease on Biopsy
Hypertensive Nephrosclerosis 6 (15)
Diabetic Nephropathy 4 (10)
Serum Creatinine (μmol/L) (IQR)





Presumed Cause of AIN
Unknown (n = 14) 240 (164–439)
Antibiotic (n = 7) 430 (274–454)
Non-Steroidal Anti-Inflammatory Drugs 219 (117-248)
(NSAIDS) (n=5)
PPI/H2 antagonist (n=4) 289 (245-332)
Immune mediated diseases (n=7) 178 (125-217)
Other (n=3) 388 (248-473)
P 0.16
Treatment
Steroid therapy 237 (164-332)
No treatment given 260 (164-430)
P 0.59
Co-existent Disease on Biopsy
Hypertensive Nephrosclerosis 330 (171-436)
Diabetic Nephropathy 244 (168-245)
No co-existent disease 242 (162-347)
P 0.55
AKIN Severity (n=12)*
1 (7) 164 (140-210)
2 (3) 197 (155-268)
3 (6) 380 (286-442)
P 0.01
*Only 12 patients had serum creatinine measured 3-12 months prior to
renal biopsy
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Over half the patients received steroid treatment (23
patients; 57.5%). The majority of these were given a
course of high dose oral prednisone (19 patients; 83%),
while three were given intravenous methylprednisone in-
duction followed by high dose oral prednisone and one
was given high dose prednisone and azathioprine. Men
and women were treated at similar rates with 12 women
(55%) and 11 men (61%) receiving treatment. The major-
ity of patients with either NSAID (4/5) or immune medi-
ated AIN (6/7) received treatment while those with
antibiotic use, PPI/H2 use or an unknown cause of AIN
were less likely to receive steroid therapy (7/14, 3/7 and 2/
4 patients, respectively). Patients who received steroid
treatment had on average lower serum creatinines com-
pared to those who did not receive treatment. The major-
ity of patients who did not receive treatment had evidence
of interstitial fibrosis and tubular atrophy on biopsy (13
patients; 76%) compared to patients who did receive ther-
apy (5 patients 21%) and this may explain the difference in
the median serum creatinine between the two groups.
Sixteen patients had serum creatinines measured in
the 3–12 months prior to biopsy. AKIN stage was calcu-
lated for these patients and as expected the serum creat-
inines by stage were significantly different.
Twenty-eight patients had a measured serum creatin-
ine two weeks post biopsy (see Table 4). The degree of
creatinine elevation did not differ by gender, cause of
AIN, treatment given, co-existent disease on biopsy or
urinary indices. At two weeks post biopsy the majority
of patients had an improvement in serum creatinine
(79%), and this was not modulated by patient gender,
cause of AIN or co-existent disease on biopsy. The
AKIN stage of AKI did not affect the rate of renal recov-
ery, with minimal difference in serum creatinine at two
weeks post biopsy between stages.
Twenty-five patients had a final serum creatinine mea-
sured at least 3 months after biopsy. There was signifi-
cant variation between the time of biopsy and final
recorded serum creatinine that limited analysis (range
0.3–9.6 years from date of biopsy). The median serum
creatinine on the last recorded measure was 99 μmol/L
(IQR 90–135). The median serum creatinine on the last
recorded serum creatinine was lower in patients who
had received steroid therapy (92 μmol/L; IQR 76–107)
compared to those who did not receive therapy
(116 μmol/L; IQR 101–127) though this difference did
not reach significance. Two patients required renal re-
placement therapy (RRT) at two weeks and three pa-
tients (including those at two weeks) required long term
RRT. Two of the three patients who required long term
RRT had co-existent CKD on renal biopsy.
Eight patients died over the course of the 16-year
period reviewed. The cause of death was not recorded
in the clinical record. The median age at death was
66.2 years (IQR 55.2–75.4). Two patients died within
2 weeks of their diagnosis. The median time to death
from biopsy was 3.0 years (IQR 0.4–7.2). Two of the
deceased patients had required long term RRT prior
to their death. There was an equal distribution of
gender in these patients. The most common identified
cause of AIN in patients who died was antibiotics as-
sociated AIN (3 patients) however 5 patients with an
unknown cause of AIN also died. These patients had
significantly higher rates of hypertension (87.5% de-
ceased vs. 39% alive; p < 0.001). Rates of other co-
morbidities were similar.
Discussion
The present study was the first to investigate rates
of biopsy confirmed AIN in Australia and, consistent
with the findings reported by the AIHW [6], it iden-
tified a significant increase in the number of patients
diagnosed with acute interstitial nephritis over the
16-year period reviewed. Importantly, our findings
are also suggestive of a recently emerging increase in
the number of young females with biopsy proven
AIN; from 2008 onwards all patients with immune
mediated AIN were under the age of 55 (median age
40.7 yrs) and the majority were women (71%). This
is in line with the findings described by the AIHW,
who noted an increase in acute tubulo-interstitial
nephritis in women less than fifty-five years of age.
Indeed, the time period over which rates of immune
mediated AIN increased (0 patients from 2000 to
2007 vs 7 patients from 2008 to 2015) is similar to
that described in the AIHW report. Due to the small
sample size of the current study, however, further
research exploring larger cohorts over longer time-
periods is required to corroborate this trend.
Table 3 AIN Etiology
Presumed Cause of AIN Total (%) Male (%) Female (%)
Unknown 14 (35) 10 (56) 4 (18)
Antibiotic 7 (17.5) 3 (17) 4 (18)
Penicillin 4 (10) 1 (6) 3 (14)
Ciprofloxacin 1 (2.5) 1(6) 0 (0)
Nitrofurantoin 1 (2.5) 0 (0) 1 (5)
Vancomycin 1 (2.5) 1 (6) 0 (0)
NSAID 5 (12.5) 1 (6) 4 (18)
PPI/H2 antagonist 4 (10) 1 (6) 3 (14)
Immune mediated diseases 7(17.5) 2 (11) 5 (23)
TINU 4 (10) 1 (6) 3 (14)
Sarcoidosis 2 (5) 1 (6) 1 (5)
Sjogren’s Syndrome 1 (2.5) 0 (0) 1 (5)
Other 3 (7.5) 1 (6) 2 (9)
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There are several possible explanations for the rising
incidence of immune mediated AIN in younger women
seen in our study. Firstly, multiple studies have shown
that rates of autoimmune diseases worldwide (including
causes of AIN such as Sjogren’s syndrome and sarcoid-
osis) are increasing [8]. This trend is seen nationally in
Table 4 Median serum creatinine (μmol/L), delta serum creatinine improvement and the percentage of patients with decreased
serum creatinine at two week post biopsy
N = 28 Median SCr at
2 weeks (IQR)
Decrease in SCr
at 2 weeks (IQR)
Percentage patient with
decreased SCr at 2 weeks (%)
All patients (28) 136 (112–197) 93 (14–158) 79
Gender
Male (14) 133 (112–185) 123 (87–170) 86
Female (14) 141 (119–119) 58 (4–104) 71
P 0.66 0.18
Comorbidities
Ischaemic Heart Disease (5) 193 (159–209) 124 (68–152) 100
Hypertension (10) 129 (113–163) 110 (6–209) 70
Dyslipidaemia (7) 193 (133–265) 88 (47–138) 86
Diabetes Mellitus (type 1 or 2) (9) 170 (159–290) 88 (30–124) 78
Autoimmune conditions (6) 129 (113–141) 44 (113–141) 67
PPI use (10) 173 (115–244) 91 (51–170) 90
Cancer (9) 129 (112–193) 90 (3–176) 78
Mental and Behavioural condition (5) 208 (142–290) 96 (68–188) 100
Presumed Cause of AIN
Unknown (9) 170 (114–248) 90 (−3–146) 67
Antibiotic (5) 127 (112–131) 176 (68–303) 100
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) (3) 139 (128–149) 88 (43–105) 67
PPI/H2 antagonist (4) 184 (129–245) 72 (39–130) 100
Immune mediated diseases (6) 119 (99–136) 90 (16–104) 67
Other (1) 314 241 100
P 0.29 0.43
Treatment
Steroid therapy (16) 135 (110–159) 189 (14–158) 81
No treatment given (12) 154 (113–218) 102 (34–170) 75
P 0.59 0.58
Co-existent Disease on Biopsy
Hypertensive Nephrosclerosis (3) 157 (143–176) 124 (64–214) 100
Diabetic Nephropathy (3) 170 (116–231) –3 (−4–21) 33%
No co-existent disease (22) 134 (112–196) 96 (36–170) 82
P 0.79 0.15
AKIN Severity (n = 13)
1 (5) 159 (94–170) 3 (−6–18) 60
2 (3) 119 (115–204) 119 (115–204) 67
3 (5) 112 (102–127) 228 (176–303) 100
P 0.65 0.01
Renal Replacment Therapy N (%)
RRT at two weeks 2 (5)
RRT at 3 months or later 3 (7.5)
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Australia with increasing incidence of asthma, food aller-
gies and anaphylaxis over the last 20 years [9]. Secondly,
autoimmune conditions are more common in women
compared to men [10] and an increasing incidence of
immune mediated AIN would have a more noticeable ef-
fect on the number of women diagnosed with AIN.
Thirdly, immune conditions associated with immune
mediated AIN such as TINU, sarcoidosis or Sjogren’s
syndrome are more common in younger women and an
increase in these conditions would likely lead to a
disproportionate increase in women developing AIN.
The current findings also confirm that while AIN can
occur in any age group, increased use of NSAIDS, anti-
biotics and PPIs combined with higher rates of renal im-
pairment put elderly patients at greater risk [11].
Specifically, patients with PPI/H2-induced AIN and
antibiotic-induced AIN tended to be older (median age
72.3 years and 66.8 years, respectively). Patients with
NSAID use were predominantly female (80%) and youn-
ger than other patients with a drug induced AIN with a
median age of 60.3 yrs. Also, NSAID associated AIN
only occurred from 2008 onwards and this trend may
also be contributing to the increase in AIN in younger
women seen in our study and by the AIHW. It has been
decades since NSAID use among young Australian
women was linked with kidney injury [12], with more re-
cent Australian studies showing that NSAID use in
Australia is more common in elderly patients [13, 14]. In
contrast, our findings suggest a reversion to previous
community behaviors of analgesic overuse among youn-
ger, predominantly female cohorts.
The majority of AIN patients have a benign course
and a complete or partial renal recovery [1, 11]. Al-
though follow-up data was only available for some of
the patients in this study, it indicated that most pa-
tients had a marked improvement in serum creatinine
at two weeks (median sCr 136 μmol/L) and near
complete renal recovery on the final serum creatinine
measured (median sCr 99 μmol/L). This improvement
was independent of age, gender, patient co-morbidity
or cause. Only 3 patients required RRT, and two of
these had pre-existing CKD.
The treatment of AIN is largely empiric, with with-
drawal or treatment of the causative agent the most ef-
fective intervention [1]. Traditionally, a course of high
dose oral prednisone (with or without intravenous
methylprednisone) has been prescribed, particularly in pa-
tients with an idiopathic or immune mediated cause. Re-
ports on the effectiveness of steroids in both these and
drug induced AIN is unproven and based on evidence
from uncontrolled, retrospective studies [1, 2, 5, 11]. The
present findings corroborate these previous results; steroid
treatment did not make a significant difference in renal
function at two weeks and on the final serum creatinine
measured. However, follow-up data was available for a
proportion of our patient cohort and conclusions should
be tentatively drawn.
In addition to the sample size issues already discussed,
other factors should be taken into consideration when
interpreting the present results. Being a single center
study it is possible that our findings are not representa-
tive of national trends. Further investigations across
multiples centers nationally are necessary in order to ob-
tain a representative Australian sample. Patients with
mild AKI or a typical presentation of AIN may not have
undergone renal biopsy and thus may be underrepre-
sented in our findings. By only reviewing patients who
have biopsy proven AIN we include only a small fraction
of those who are clinically diagnosed with AIN, as those
with less severe AKI do not generally proceed to renal
biopsy. The complement of nephrologists changed over
the course of the study and the decision to undertake a
renal biopsy was not standardized. Referring patterns
from other specialists and clinics may have changed over
the course of the study and could have contributed to an
increase in the incidence of AIN. And lastly, our study
excluded patients with pyelonephritis. Because of this,
we were unable to compare rates of AIN to those of
acute pyelonephritis and thus our findings cannot rule
out the possibility that the increase in acute tubulo-
interstitial nephritis reported by the AIHW was due to
increased rates of both acute pyelonephritis and AIN.
Further investigations are required to adjudicate this
possibility.
Conclusions
Our study demonstrates a significant increase in AIN
over the last 16 years and supports the AIHW’s find-
ing of increasing rates of AIN in Australia. While
rates of both men and women with AIN were shown
to increase in our study, a trend of increasing rates
of younger women with immune mediated AIN and
NSAID associated AIN, notably in the study’s last
eight years, was also observed. Although preliminary,
these results support the trends identified by the
AIHW and suggest that younger women may have a
heightened risk of both immune mediated and
NSAID induced acute interstitial nephritis.
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